Half-year report · Q2
2160.TEDINET S100U8GV
Period2024-01-01 → 2024-06-30
Filed2024-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 62
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.7bn | 2024-01-01 → 2024-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥5.8bn | 2024-04-01 → 2024-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥26.0bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥14.1bn | 2023-01-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥9.9bn | 2023-04-01 → 2023-06-30d | Cons. | Revenue IFRS |
| Operating income | ¥1.8bn | 2024-01-01 → 2024-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥522m | 2024-04-01 → 2024-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥5.5bn | 2023-01-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥5.1bn | 2023-04-01 → 2023-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥831m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥996m | 2024-04-01 → 2024-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥12.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥5.1bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.2bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥330m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥1.1bn | 2024-04-01 → 2024-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥8.1bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.7bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥74m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥1.4bn | 2024-04-01 → 2024-06-30d | Cons. | Profit loss IFRS |
| Net income | ¥9.5bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥4.0bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥4.4bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥69.0bn | at 2024-06-30 | Cons. | Assets IFRS |
| Total assets | ¥62.4bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥45.1bn | at 2023-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥29.4bn | at 2024-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥26.3bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥39.6bn | at 2024-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥36.1bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥24.8bn | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥36.8bn | at 2024-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥33.8bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥23.0bn | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥16.3bn | at 2024-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.1bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥1.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥6.5bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥872m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥5.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥6.8bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.6bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥186m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥10.7bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥3.9bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥6.61 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-22.49 | 2024-04-01 → 2024-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥169.5 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥34.93 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥34.99 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥6.37 | 2024-01-01 → 2024-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-22.49 | 2024-04-01 → 2024-06-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥165.56 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥34.81 | 2023-01-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥34.88 | 2023-04-01 → 2023-06-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 53.4% | at 2024-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.2% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 51.0% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.6bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.6bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥676m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥9.1bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥9.1bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥1.1bn |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥11.7bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥11.7bn |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-06-30 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-06-30 | −¥23m |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥1.4bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥1.3bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥23m |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥512m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥12.8bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥12.8bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥5.0bn |
| —segment total | revenue | 2023-01-01 → 2023-06-30 | ¥14.1bn |
| —segment total | revenue external | 2023-01-01 → 2023-06-30 | ¥14.1bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥23m |
| —segment total | segment profit | 2023-01-01 → 2023-06-30 | ¥5.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 740
| Item | Context | Value | Unit |
|---|---|---|---|
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Current period end date | FilingDateInstant | 2024-06-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Comparative period end date | FilingDateInstant | 2023-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)株式会社ＳＢＩ証券 | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区六本木１丁目６番１号 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京短資株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋室町４丁目４－１０ | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | PERSHING-DIV. OF DLJ SECS. CORP. | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | ONE PERSHING PLAZA JERSEY CITY NEW JERSEY U.S.A. | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | MACQUARIE BANK LIMITED DBU AC | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | LEVEL 6, 50 MARTIN PLACE SYDNEY NSW 2000 AUSTRALIA | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | NATIONAL FINANCIAL SERVICES LLC | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | 1585 BROADWAY NEW YORK, NY 10036 U.S.A. | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | NOMURA PB NOMINEES LIMITED OMNIBUS-MARGIN (CASHPB) | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | 1 ANGEL LANE, LONDON, EC4R 3AB, UNITED KINGDOM | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |